Hosokawa S, Yoshida O
Utano National Hospital, Kyoto, Japan.
Nephron. 1993;65(3):414-7. doi: 10.1159/000187522.
We examined the relationship between recombinant human erythropoietin (rHuEPO) therapy and serum levels of the trace elements aluminum, silicon, zinc, nickel, and manganese in 55 patients undergoing chronic hemodialysis (HD) in whom rHuEPO (for 12 weeks) was effective in reducing anemia, and in 55 patients undergoing HD without rHuEPO treatment. In the rHuEPO group, serum Al level was significantly decreased and Si level showed a tendency to decrease. Zn, Ni, and Mn levels, however, were significantly increased.
我们研究了重组人促红细胞生成素(rHuEPO)治疗与55例接受慢性血液透析(HD)患者血清中铝、硅、锌、镍和锰等微量元素水平之间的关系。这55例患者接受了12周的rHuEPO治疗,且该治疗有效减轻了贫血症状;同时还研究了55例未接受rHuEPO治疗的HD患者。在rHuEPO治疗组中,血清铝水平显著降低,硅水平有下降趋势。然而,锌、镍和锰的水平显著升高。